Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition

Nicola Giuliani, Vittorio Rizzoli, G. David Roodman

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.

Original languageEnglish (US)
Pages (from-to)3992-3996
Number of pages5
JournalBlood
Volume108
Issue number13
DOIs
StatePublished - Dec 15 2006
Externally publishedYes

Fingerprint

Bone Diseases
Osteoblasts
Multiple Myeloma
Bone
Bone and Bones
Osteogenesis
Osteoclasts
Plasma Cells
Plasmas
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Multiple myeloma bone disease : Pathophysiology of osteoblast inhibition. / Giuliani, Nicola; Rizzoli, Vittorio; Roodman, G. David.

In: Blood, Vol. 108, No. 13, 15.12.2006, p. 3992-3996.

Research output: Contribution to journalArticle

Giuliani, Nicola ; Rizzoli, Vittorio ; Roodman, G. David. / Multiple myeloma bone disease : Pathophysiology of osteoblast inhibition. In: Blood. 2006 ; Vol. 108, No. 13. pp. 3992-3996.
@article{e1bd46b717af4bde85434cb30d8ff33a,
title = "Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition",
abstract = "Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.",
author = "Nicola Giuliani and Vittorio Rizzoli and Roodman, {G. David}",
year = "2006",
month = "12",
day = "15",
doi = "10.1182/blood-2006-05-026112",
language = "English (US)",
volume = "108",
pages = "3992--3996",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Multiple myeloma bone disease

T2 - Pathophysiology of osteoblast inhibition

AU - Giuliani, Nicola

AU - Rizzoli, Vittorio

AU - Roodman, G. David

PY - 2006/12/15

Y1 - 2006/12/15

N2 - Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.

AB - Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.

UR - http://www.scopus.com/inward/record.url?scp=33751193178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751193178&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-05-026112

DO - 10.1182/blood-2006-05-026112

M3 - Article

C2 - 16917004

AN - SCOPUS:33751193178

VL - 108

SP - 3992

EP - 3996

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -